Newron Pharmaceuticals SpA (NWRN) – Company Profile and SWOT Analysis

Newron Pharmaceuticals SpA (NWRN) – Company Profile & SWOT Analysis, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.

Key Highlights

Newron Pharmaceuticals SpA (Newron) is a biopharmaceutical company. It focuses on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain. The company’s marketed the product, Xadago (safinamide), is developed as an adjunctive therapy for any stage of Parkinson's disease. Newton's other products in the pipeline include ralfinamide for neuropathic pain; and Evenamide (NW-3509) for the treatment of schizophrenia. The company has development and commercialization collaborations with Zambon and Meiji Seika Pharma Co Ltd. The company has an international presence, with products approved in countries including Switzerland, the US, Australia, Canada, and Japan. Newron is headquartered in Bresso, Milan, Italy.

Scope

• Detailed information on Newron Pharmaceuticals SpA required for business and competitor intelligence needs

• A study of the major internal and external factors affecting Newron Pharmaceuticals SpA in the form of a SWOT analysis

• An in-depth view of the business model of Newron Pharmaceuticals SpA including a breakdown and examination of key business segments

• News about Newron Pharmaceuticals SpA, such as business expansion, restructuring, and contract wins

• Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

• Gain understanding of Newron Pharmaceuticals SpA and the factors that influence its strategies.

• Track strategic initiatives of the company and latest corporate news and actions.

• Assess Newron Pharmaceuticals SpA as a prospective partner, vendor or supplier.

• Support sales activities by understanding your customers' businesses better.

• Stay up to date on Newron Pharmaceuticals SpAs business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Silence Therapeutics Plc

Biofrontera AG

AC Immune SA

Biotie Therapies Ltd

Santhera Pharmaceuticals Holding AG

Pharming Group NV

Nanobiotix SA

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Newron Pharmaceuticals SpA - Key Facts

Newron Pharmaceuticals SpA - Key Employees

Newron Pharmaceuticals SpA - Key Employee Biographies

Newron Pharmaceuticals SpA - Major Products and Services

Newron Pharmaceuticals SpA - History

Newron Pharmaceuticals SpA - Company Statement

Newron Pharmaceuticals SpA - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 – Company Analysis

Company Overview

Newron Pharmaceuticals SpA - Business Description

R&D Overview

Newron Pharmaceuticals SpA - Corporate Strategy

Newron Pharmaceuticals SpA - SWOT Analysis

SWOT Analysis - Overview

Newron Pharmaceuticals SpA - Strengths

Newron Pharmaceuticals SpA - Weaknesses

Newron Pharmaceuticals SpA - Opportunities

Newron Pharmaceuticals SpA - Threats

Newron Pharmaceuticals SpA - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024

Newron Pharmaceuticals SpA, Recent Deals Summary

Section 5 – Company’s Recent Developments

Sep 19, 2024: Newron Reports H1 2024 Results and Announces Business Update

Sep 19, 2024: Newron Presents H1 2024 Results and Provides Business Update

Mar 19, 2024: Newron Presents 2023 Financial Results and Provides 2024 Outlook

Mar 15, 2024: Newron Announces Agreement with the European Investment Bank (EIB) to Extend the Near-Term Tranche Repayment Dates of Its 2018 Financing Agreement

Oct 02, 2023: Newron Appoints Margarita Chavez as Board Advisor

Aug 04, 2023: Newron Announces H1 2023 Results and Provides R&D Update

Apr 18, 2023: EQS-News: Newron announces AGM 2023 results

Mar 14, 2023: Newron announces 2022 financial results and provides outlook for 2023

Section 6 – Appendix

Methodology

Ratio Definitions

About MarketLine

Contact Us

Disclaimer

List of Tables

List of Tables

Newron Pharmaceuticals SpA, Key Facts

Newron Pharmaceuticals SpA, Key Employees

Newron Pharmaceuticals SpA, Key Employee Biographies

Newron Pharmaceuticals SpA, Major Products and Services

Newron Pharmaceuticals SpA, History

Newron Pharmaceuticals SpA, Subsidiaries

Newron Pharmaceuticals SpA, Key Competitors

Newron Pharmaceuticals SpA, Ratios based on current share price

Newron Pharmaceuticals SpA, Annual Ratios

Newron Pharmaceuticals SpA, Annual Ratios (Cont…1)

Newron Pharmaceuticals SpA, Annual Ratios (Cont…2)

Newron Pharmaceuticals SpA, Interim Ratios

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024

Newron Pharmaceuticals SpA, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

Newron Pharmaceuticals SpA, Performance Chart (2019 – 2023)

Newron Pharmaceuticals SpA, Ratio Charts

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024

Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

    Pricing

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports